

Informazione Regolamentata n. 0957-72-2020

Data/Ora Ricezione 06 Agosto 2020 07:24:58

MTA

Societa' : DiaSorin

Identificativo : 135961

Informazione

Regolamentata

Nome utilizzatore : DIASORINN02 - Fava

Tipologia : REGEM

Data/Ora Ricezione : 06 Agosto 2020 07:24:58

Data/Ora Inizio : 06 Agosto 2020 07:24:59

Diffusione presunta

Oggetto : DiaSorin announces the launch of its new

CE marked LIAISON Testosterone xt test


for the dosage of testosterone

Testo del comunicato

Vedi allegato.









DIASORIN ANNOUNCES THE LAUNCH OF ITS NEW CE MARKED LIAISON® TESTOSTERONE XT TEST FOR THE DOSAGE OF TESTOSTERONE

Saluggia - August 6, 2020 - DiaSorin (FTSE MIB: DIA) announced today that it has CE marked and launched its new LIAISON® Testosterone xt test for the dosage of testosterone. The assay is designed for use with the LIAISON® XL instrument.

The LIAISON® Testosterone xt test is an evolution of the LIAISON Testosterone test currently available and is a diagnostic marker for the detection of fertility disorders, such as the hypogonadism in men and hyperandrogenism in women.

The new test enriches the existing fertility and endocrinology tests panel, currently available on the LIAISON® XL, providing a support to the clinicians in the diagnosis and monitoring phases of a number of disorders linked to the reproductive system of both men and women.

Available market data show that between 10% and 15% of couples worldwide experience fertility and conception issues. Infertility is still an extremely complex clinical condition that requires a number of different hormonal parameters' evaluation to start appropriate therapies or dedicated clinical procedures.

"The launch of the LIAISON® Testosterone xt assay proves once again our dedication in researching, developing and commercializing products that can provide solid answers to the laboratories' needs and, to the patients' ones", commented Chen Even, Chief Commercial Officer of the DiaSorin Group. "The new test adds up to the existing panel for the dosage of hormones, strengthening our current market positioning as diagnostic specialists and confirming our calling to invest in research and innovation".

For additional information, please contact:

Riccardo Fava

Corporate Vice President Communication & Investor Relations Tel: +39.0161.487988 riccardo.fava@diasorin.it

Emanuela Salvini

Investor Relator Tel: +39.0161.487567 emanuela.salvini@diasorin.it

DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field, with 26 companies, 4 branches, 5 manufacturing facilities and 5 research and development centers.

For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The extensive diagnostic testing offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasoringroup.com

Fine Comunicato n.0957-7	Fine	Comunicato	n.0957-72	2
--------------------------	------	------------	-----------	---

Numero di Pagine: 3